From the Journals

Counsel women against unnecessary prophylactic mastectomies

View on the News

Survival isn’t the only issue

Although CPM is not associated with improved survival, it reduces the risk of contralateral breast cancer, and the significance of this fact to some patients should not be minimized.

As we move toward an ever-more personalized, patient-centered approach to care, we must thoughtfully weigh the balance between respecting patients’ preferences and leaving them with the long-term consequences associated with an “unnecessary” operation. For many women who choose CPM, the peace of mind associated with a reduced – albeit not eliminated – likelihood of subsequent cancer justifies the additional surgery and the potential attendant complications, even if the avoided cancer might not have actually shortened their lives. Furthermore, concerns about postsurgical cosmesis and symmetry can significantly affect the self-esteem of young women with breast cancer and affect their quality of life as much as, if not more than, concerns surrounding mortality and risk reduction.

Patients should be supported to make their own value-based medical decisions, but the medical community must continue to do its part to educate patients on the negligible benefits of this procedure and help to overcome the fears and misperceptions that often drive this decision.

Oluwadamilola M. Fayanju, MD, and E. Shelley Hwang, MD, are at Duke University in Durham, N.C. Their comments are adapted from an editorial (JAMA Surg. 2016 Dec 21. doi: 10.1001/jamasurg.2016.4750). They reported having no conflicts of interest.


 

FROM JAMA SURGERY

Women with breast cancer are much less likely to opt for contralateral prophylactic mastectomies if they know it won’t prolong their lives, according to a survey of 2,402 women with unilateral stage 0-II breast cancer.

Contralateral prophylactic mastectomy (CPM) – removing the healthy breast along with the cancerous one – is on the rise for early-stage, unilateral breast cancer because of “celebrity exposure and publicity,” said investigators led by Reshma Jagsi, MD, of the University of Michigan, Ann Arbor (JAMA Surg. 2016 Dec 21. doi: 10.1001/jamasurg.2016.4749).

CPM might make sense for women at genetic risk for breast cancer, like actress Angelina Jolie – who made headlines in 2013 when she opted for double mastectomy – but the survey found that nearly one in five women with no genetic risks also opted for CPM when their surgeons made no recommendation either way.

When surgeons advised against the procedure, the number fell to about 2%. Meanwhile, many women said their surgeons stayed silent on the issue, which is a problem, according to the investigators.

Overall, about 44% of women in the survey considered CPM, but just 38% of them said they knew that CPM didn’t improve survival for all women with breast cancer.

“Some patients may pursue CPM for cosmetic symmetry or other reasons. However, it is not clear that average-risk patients who choose CPM truly understand that it will not improve their survival or alter recurrence risk,” the investigators noted.

Surgeons’ knowledge and communication practices could be targets for quality improvement interventions, the investigators wrote. “Our findings should motivate surgeons to broach these difficult conversations with their patients, to make their recommendations clear, and to promote patients’ peace of mind by emphasizing how other treatments complement surgery to reduce the risk of both tumor recurrence and subsequent cancer development,” they said.

Women in the study were identified through the Surveillance Epidemiology and End Results (SEER) registries of Los Angeles County and Georgia. They were 62 years old, on average. CPM was associated with younger age, white race, higher educational level, family history, and private insurance.

The National Institutes of Health supported the study. Dr. Jagsi reported having no disclosures. A coauthor reported research funding from Myriad Genetics, Invitae, Ambry Genetics, GeneDx, and Genomic Health.

Recommended Reading

VIDEO: No effect of BRCA status on overall outcomes in early-onset breast cancer
MDedge Hematology and Oncology
Aromatase inhibitor effect on endothelial function may lead to CVD
MDedge Hematology and Oncology
VIDEO: Abemaciclib reduces Ki67 expression in early HR+/HER2– breast cancer
MDedge Hematology and Oncology
VIDEO: Watson for Oncology offers electronic curbside consults in breast cancer
MDedge Hematology and Oncology
It’s elementary: Watson aids in breast cancer decisions
MDedge Hematology and Oncology
VIDEO: AIs associated with endothelial dysfunction, a predictor of CVD
MDedge Hematology and Oncology
Cooling device reduces breast cancer–related alopecia during chemotherapy
MDedge Hematology and Oncology
PIK3 inhibitor gives slight PFS edge at high cost for HR+/HER2– advanced breast cancer
MDedge Hematology and Oncology
VIDEO: Watson helps oncologists sleuth out best options in breast cancer
MDedge Hematology and Oncology
SLND after neoadjuvant chemo is feasible, but more study needed
MDedge Hematology and Oncology